A Review of Alprazolam Use, Misuse, and Withdrawal
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index; 6 of the 77 sources its claims cite were checked for support.
Abstract
Alprazolam is one of the most widely prescribed benzodiazepines for the treatment of generalized anxiety disorder and panic disorder. Its clinical use has been a point of contention as most addiction specialists consider it to be highly addictive, given its unique psychodynamic properties which limit its clinical usefulness, whereas many primary care physicians continue to prescribe it for longer periods than recommended. Clinical research data has not fully shed light on its “abuse liability,” yet it is one of the most frequently prescribed benzodiazepines. “Abuse liability” is the degree to which a psychoactive drug has properties that facilitate people misusing it, or becoming addicted to it, and is commonly used in the literature. We have replaced it in our manuscript with “misuse liability” as it reflects a more updated terminology consistent with the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). In this paper, we have reviewed alprazolam's indications for use, its effect on pregnant women, misuse liability, withdrawal syndrome, pharmacodynamic properties, and suggest better clinical prescription practice of alprazolam by presenting an indepth theory of its clinical effects with use and withdrawal.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 1 Not valid · 54 Not checked · 7 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“more than half of the patients who visited hospital and “community practice-based research network” received benzodiazepine prescriptions at least once from their primary care physician (PCP).”
§ A Review of Alprazolam Use, Misuse, and Withdrawal > Abstract
What the sources say
- Disputedcites Kroll et al., 2016 matched to “Benzodiazepines are prescribed more frequently to patients already at risk for benzodiazepine-related adverse events in primary care” (2016) sourceExperimental — accuracy not yet measured
The Cohort Characteristics section states that among 65,912 patients who visited the ten BWPC PBRN practices, only 15% (9,821) received at least one benzodiazepine prescription, and that of those recipients only 44% received at least one from their PCP of record — the Discussion restates this as 'close to half,' not more than half. The citing sentence therefore both inverts the magnitude (>50% vs 44%) and shifts the denominator from benzodiazepine recipients to all patients who visited the network. (LLM, conf=0.80)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“when alprazolam was involved, the median length of stay (LOS) was 19 hours, which was 1.27 (95% confidence interval [CI] 1.04, 1.54) times longer compared with other benzodiazepines”
§ A Review of Alprazolam Use, Misuse, and Withdrawal > Abstract
What the sources say
- Supportedcites Isbister et al., 2004 matched to “Alprazolam is relatively more toxic than other benzodiazepines in overdose” (2004) source
The Abstract states 'The median LOS for alprazolam overdoses was 19 h which was 1.27 (95% CI 1.04, 1.54) times longer compared with other benzodiazepines by multiple linear regression', and the Results (Alprazolam overdose, p. section) give the median LOS of 19 h (IQR 13-39 h) across the 131 alprazolam admissions. Table 3 (Discussion) shows the multivariate ln[LOS] model with an alprazolam coefficient of 0.24 (95% CI 0.04, 0.43) against the 'other benzodiazepine' reference, i.e. adjusted for age, dose, gender, time to presentation and co-ingestants, matching the claim's 1.27 ratio after multivariate adjustment. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“patients were 2.06 (95% CI 1.27, 3.33) times more likely to be admitted to the intensive care unit (ICU) compared with other benzodiazepines after multivariate analysis adjusting for age, dose, sex, time to ingestion, and co-ingested drugs (Isbister et al., 2004).”
§ A Review of Alprazolam Use, Misuse, and Withdrawal > Abstract
What the sources say
- Supportedcites Isbister et al., 2004 matched to “Alprazolam is relatively more toxic than other benzodiazepines in overdose” (2004) source
The paper’s Abstract reports that 22% of patients with alprazolam overdoses were admitted to ICU and gives an adjusted relative likelihood of 2.06 (95% CI 1.27–3.33) versus other benzodiazepines. It lists the same adjustment variables as the citing sentence. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Those clinicians were found to prescribe benzodiazepines disproportionately to patients with at least some known risk factors for benzodiazepine-related adverse events including increased age, pulmonary diseases, and other substance use disorders (Kroll et al., 2016).”
§ A Review of Alprazolam Use, Misuse, and Withdrawal > Abstract
What the sources say
- Supportedcites Kroll et al., 2016 matched to “Benzodiazepines are prescribed more frequently to patients already at risk for benzodiazepine-related adverse events in primary care” (2016) source
The Discussion explicitly reports that clinicians prescribed benzodiazepines disproportionately to patients with known risk factors, including increased age, pulmonary diseases, and substance use disorders. The Benzodiazepine Prescribing section also reports higher prescribing among older patients and those with COPD, sleep apnea, asthma, or substance-abuse diagnoses. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Alprazolam use for merely 1 week produces discontinuation symptoms in mice (Galpern et al., 1991)”
§ A Review of Alprazolam Use, Misuse, and Withdrawal > ALPRAZOLAM WITHDRAWAL SYNDROME
What the sources say
- Supportedcites Galpern et al., 1991 matched to “Chronic benzodiazepine administration” (1991) source
The DISCUSSION section states that 'alprazolam administration for 1 week in mice produced a discontinuation' effect, and the Abstract/Open-field activity sections (pp. corresponding to Results) report the supporting data: increased open-field activity at 4 days after discontinuing alprazolam (2 mg/kg/day for 7 days), along with GABAA receptor binding and GABA-dependent chloride uptake increases. Although the mouse model is described as previously reported (Ref. 10), this paper itself reports and relies on those discontinuation findings in its own ALP/VEH groups, so the attribution holds. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
31 more claims · 1 with their cited sources checked
Create a free account to see all 67 claims and to verify the 71 references still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 5
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alprazolam tends to be difficult to taper given that it is short-acting and has no active metabolites.62”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, alprazolam may exhibit higher cross-tolerance with other BZDs, and some patients may have challenges with this transition.62”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, some newer documents specifically advise against the use of alprazolam given its rapid onset and shorter-half life; pharmacokinetic properties that increase its potential for withdrawal and misuse.152”
From Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review (2024) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It should be noted that alprazolam—which is unique in having a very short half-life, rapid onset of action, and no active metabolites—tends to be associated with a more rapid onset of physical dependence.62”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Alprazolam Use, Misuse, and Withdrawal > ALPRAZOLAM WITHDRAWAL SYNDROME
“However, interestingly, both chlordiazepoxide and diazepam were found to be ineffective in preventing alprazolam withdrawal symptoms in 2 separate cases (Schweizer et al., 1993; Sachdev et al., 2014).”
§ A Review of Alprazolam Use, Misuse, and Withdrawal > References
“Sachdev G Gesin G Christmas AB Failure of lorazepam to treat alprazolam withdrawal in a critically ill patient World J Crit Care Med 2014 3 42 24834401 PMC4021153”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Alprazolam Use, Misuse, and Withdrawal > ALPRAZOLAM WITHDRAWAL SYNDROME
“It is also consistent with open-label reports and a double-blind study supporting the use of carbamazepine in benzodiazepine withdrawal (Björkqvist et al., 1976).”
§ A Review of Alprazolam Use, Misuse, and Withdrawal > References
“Björkqvist SE Isohanni M Mäkelä R Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo Acta Psychiatr Scand 1976 53 333 342 785949”
Citations
Cites
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Ballenger, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290027004 · Cited by 564
Neuroadaptations involved in amphetamine and cocaine addiction
White, F. J., & Kalivas, P. W. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00072-6 · Cited by 509
Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.5.592 · Cited by 434
Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant
Iqbal, M. M., Sobhan, T., & Ryals, T. (2002) · Psychiatric Services · doi:10.1176/appi.ps.53.1.39 · Cited by 427 · cited 4×
“Retrospective studies evaluating pregnancy outcomes of women exposed to alprazolam during the first trimester of pregnancy found conflicting results of congenital anomalies (Iqbal et al., 2002).”
InfluentialManagement of bipolar disorder during pregnancy and the postpartum period
Yonkers, K. A., Wisner, K. L., Stowe, Z., Leibenluft, E., Cohen, L., Miller, L., Manber, R., Viguera, A., Suppes, T., & Altshuler, L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.608 · Cited by 394 · cited 1×
“To the extent that benzodiazepines are associated with teratogenic effects, many experts consider the absolute increase to be small (Dolovich et al., 1998; Yonkers et al., 2004).”
Dolovich, L. R., Addis, A., Vaillancourt, J. M. R., Power, J. D. B., Koren, G., & Einarson, T. R. (1998) · BMJ · doi:10.1136/bmj.317.7162.839 · Cited by 353
Clinical Pharmacokinetics of Alprazolam: Therapeutic Implications
Greenblatt, D. J., & Wright, C. E. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324060-00003 · Cited by 352
Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis
Barker, M. (2004) · Archives of Clinical Neuropsychology · doi:10.1016/s0887-6177(03)00096-9 · Cited by 307 · cited 2×
“Furthermore, the degree of cognitive recovery that may take place after a benzodiazepine taper is unclear, with compelling evidence not supporting full restitution of cognitive function, at least in the first 6 months after cessation, and suggestion that there may be some permanent deficits in comparison to controls (…”
Research works printed but not linked: 2
- National Collaborating Centre for Mental Health Antenatal and postnatal mental health: clinical management and service guidance—updated edition NICE guideline (CG192) London, UK British Psychological Society and The Royal College of Psychiatrists 2014 26180865
- SAMHSA Drug Abuse Warning Network, 2011: national estimates of drug-related emergency department visits Subst Abuse Mental Health Serv Administr 2013 13 4760 27631059
Cited by
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“These changes contribute to tolerance to specific BZD and dosage, mediating dependence and later withdrawal [53].”
BackgroundPrepandemic psychotropic drug status in Portugal: a nationwide pharmacoepidemiological profile
Madeira, L., Queiroz, G., & Henriques, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-33765-0 · Cited by 143
Kienitz, R., Kay, L., Beuchat, I., Gelhard, S., von Brauchitsch, S., Mann, C., Lucaciu, A., Schäfer, J.-H., Siebenbrodt, K., Zöllner, J.-P., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00940-2 · Cited by 139
The Neuropsychology of Anxiety: An enquiry into the functions of the septo-hippocampal system
McNaughton, N., & Gray, J. A. (2024) · doi:10.1093/oso/9780198843313.001.0001 · Cited by 97
Benzodiazepines and Related Sedatives
Peng, L., Morford, K. L., & Levander, X. A. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.08.012 · Cited by 86
Metadata
- Authors
- Ait-Daoud, N., Hamby, A. S., Sharma, S., & Blevins, D.
- Affiliations
- Sentara Rockingham Memorial Hospital Medical Center (US)
- ORCID
- Blevins, Derek
- Venue
- Journal of Addiction Medicine
- Published
- 2018-01
- Volume
- 12
- Issue
- 1
- Pages
- 4-10
- ISSN
- 1932-0620 (ISSN-L)
- 1935-3227
- PMC
- PMC5846112
- OpenAlex
- W2744770608
- Semantic Scholar
- 88e6c780d70e2e827c0d38a21629389eeadbf5d1
- Cited by
- 195
- References
- 67
- Citations by year
- 2026: 15 · 2025: 30 · 2024: 46 · 2023: 30 · 2022: 25 · 2021: 19 · 2020: 17 · 2019: 10 · 2018: 3
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Addiction Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (T32DA007294)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- alprazolam, benzodiazepines, benzodiazepine withdrawal syndrome, addiction, generalized anxiety disorder, panic disorder, pregnancy, pharmacodynamics, prescribing patterns, abuse liability
- MeSH terms
- Alprazolam, Anxiety Disorders, Benzodiazepines, Female, Humans, Pregnancy, Substance Withdrawal Syndrome, Panic Disorder, Prescription Drug Misuse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Review of Alprazolam Use, Misuse, and Withdrawal. https://app.cochat.ai/papers/10.1097/adm.0000000000000350
- The paper
- Ait-Daoud, N., Hamby, A. S., Sharma, S., & Blevins, D. (2018). A Review of Alprazolam Use, Misuse, and Withdrawal. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000000350
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.